ReviewHandbook of experimental pharmacology2013
Novel chemotherapeutic drugs in sphingolipid cancer research.
Review in Handbook of experimental pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 37 citations in OpenAlex.
- The role of ACER2 in intestinal sphingolipid metabolism and gastrointestinal cancers.Frontiers in immunology · 2024Review
- Surface cholesterol-enriched domains specifically promote invasion of breast cancer cell lines by controlling invadopodia and extracellular matrix degradation.Cellular and molecular life sciences : CMLS · 2022Article
- Sphingolipids and Lymphomas: A Double-Edged Sword.Cancers · 2022Review
- Alteration of cholesterol distribution at the plasma membrane of cancer cells: From evidence to pathophysiological implication and promising therapy strategy.Frontiers in physiology · 2022Review
- Overcoming Chemoresistance via Extracellular Vesicle Inhibition.Frontiers in molecular biosciences · 2021Review
- Ceramide launches an acute anti-adhesion pro-migration cell signaling program in response to chemotherapy.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020Article
- Probing compartment-specific sphingolipids with targeted bacterial sphingomyelinases and ceramidases.Journal of lipid research · 2019Article
- Ceramides bind VDAC2 to trigger mitochondrial apoptosis.Nature communications · 2019Article
- Multiple actions of doxorubicin on the sphingolipid network revealed by flux analysis.Journal of lipid research · 2019Article
- Neutral ceramidase: Advances in mechanisms, cell regulation, and roles in cancer.Advances in biological regulation · 2019Review
- Targeting Sphingosine Kinases for the Treatment of Cancer.Advances in cancer research · 2018Review
- Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach.Clinical Medicine Insights. Oncology · 2018Review
- Comparative analysis of the effects of a sphingosine kinase inhibitor to temozolomide and radiation treatment on glioblastoma cell lines.Cancer biology & therapy · 2017Article
- Biological Effects of Naturally Occurring Sphingolipids, Uncommon Variants, and Their Analogs.Neuromolecular medicine · 2016Review
- Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemia--Impact on enzyme activity and response to cytotoxics.Biochimica et biophysica acta · 2015Article
- On-tissue localization of ceramides and other sphingolipids by MALDI mass spectrometry imaging.Analytical chemistry · 2014Article
- Sphingolipids in colon cancer.Biochimica et biophysica acta · 2014Review
- The yeast sphingolipid signaling landscape.Chemistry and physics of lipids · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Sphingolipid-metabolizing enzymes are becoming targets for chemotherapeutic development with an increasing interest in the recent years. In this chapter we introduce the sphingolipid family of lipids, and the role of individual species in cell homeostasis. We also discuss their roles in several rare diseases and overall, in cancer transformation. We follow the biosynthesis pathway of the sphingolipid tree, focusing on the enzymes in order to understand how using small molecule inhibitors makes it possible to modulate cancer progression. Finally, we describe the most used and historically significant inhibitors employed in cancer research, their relationships to sphingolipid metabolism, and some promising results found in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.